Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 440

1.

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.

Morabito F, Recchia AG, Vigna E, Botta C, Skafi M, Abu-Rayyan M, Atrash M, Galimberti S, Morabito L, Al-Janazreh H, Martino M, Cutrona G, Gentile M.

Expert Opin Pharmacother. 2019 Nov 18:1-10. doi: 10.1080/14656566.2019.1689959. [Epub ahead of print]

PMID:
31738609
2.

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.

Cohen JA, Rossi FM, Zucchetto A, Bomben R, Terzi-di-Bergamo L, Rabe KG, Degan M, Steffan A, Polesel J, Santinelli E, Innocenti I, Cutrona G, D' Arena G, Pozzato G, Zaja F, Chiarenza A, Rossi D, Di Raimondo F, Laurenti L, Gentile M, Morabito F, Neri A, Ferrarini M, Fegan CD, Pepper CJ, Del Poeta G, Parikh SA, Kay NE, Gattei V.

Haematologica. 2019 Oct 3. pii: haematol.2019.228171. doi: 10.3324/haematol.2019.228171. [Epub ahead of print]

3.

The use of intraperitoneal chemotherapy for gastric malignancies.

Macrì A, Morabito F.

Expert Rev Anticancer Ther. 2019 Oct;19(10):879-888. doi: 10.1080/14737140.2019.1671189. Epub 2019 Sep 27.

PMID:
31544548
4.

Leveraging network analysis to support experts in their analyses of subjects with MCI and AD.

Lo Giudice P, Mammone N, Morabito FC, Pizzimenti RG, Ursino D, Virgili L.

Med Biol Eng Comput. 2019 Sep;57(9):1961-1983. doi: 10.1007/s11517-019-02004-y. Epub 2019 Jul 12.

PMID:
31301007
5.

The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice.

Galimberti S, Genuardi E, Mazziotta F, Iovino L, Morabito F, Grassi S, Ciabatti E, Guerrini F, Petrini M.

Front Oncol. 2019 Jun 26;9:528. doi: 10.3389/fonc.2019.00528. eCollection 2019. Review.

6.

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12.

Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L.

Cancers (Basel). 2019 Jun 26;11(7). pii: E896. doi: 10.3390/cancers11070896.

7.

A novel methodology for automated differential diagnosis of mild cognitive impairment and the Alzheimer's disease using EEG signals.

Amezquita-Sanchez JP, Mammone N, Morabito FC, Marino S, Adeli H.

J Neurosci Methods. 2019 Jul 1;322:88-95. doi: 10.1016/j.jneumeth.2019.04.013. Epub 2019 May 2.

PMID:
31055026
8.

IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia.

Reda G, Cassin R, Gentile M, Mauro FR, Giannarelli D, Fattizzo B, Barbieri M, Silvestris I, Fabris S, Morabito F, Neri A, Barcellini W, Cortelezzi A.

Leukemia. 2019 Jun;33(6):1519-1522. doi: 10.1038/s41375-018-0344-1. Epub 2019 Jan 11. No abstract available.

PMID:
30635629
9.

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.

Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R.

J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

10.

Lenalidomide for the treatment of mantle cell lymphoma.

Morabito F, Skafi M, Recchia AG, Kashkeesh A, Hindiyeh M, Sabatleen A, Morabito L, Alijanazreh H, Hamamreh Y, Gentile M.

Expert Opin Pharmacother. 2019 Apr;20(5):487-494. doi: 10.1080/14656566.2018.1561865. Epub 2019 Jan 4. Review.

PMID:
30608891
11.

A network analysis based approach to characterizing periodic sharp wave complexes in electroencephalograms of patients with sporadic CJD.

LoLo Giudice P, Ursino D, Mammone N, Morabito FC, Aguglia U, Cianci V, Ferlazzo E, Gasparini S.

Int J Med Inform. 2019 Jan;121:19-29. doi: 10.1016/j.ijmedinf.2018.11.003. Epub 2018 Nov 14.

PMID:
30545486
12.

Compressibility of High-Density EEG Signals in Stroke Patients.

Mammone N, De Salvo S, Ieracitano C, Marino S, Cartella E, Bramanti A, Giorgianni R, Morabito FC.

Sensors (Basel). 2018 Nov 23;18(12). pii: E4107. doi: 10.3390/s18124107.

13.

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F.

Eur J Haematol. 2018 Jul 24. doi: 10.1111/ejh.13149. [Epub ahead of print] No abstract available.

PMID:
30039576
14.

Permutation Jaccard Distance-Based Hierarchical Clustering to Estimate EEG Network Density Modifications in MCI Subjects.

Mammone N, Ieracitano C, Adeli H, Bramanti A, Morabito FC.

IEEE Trans Neural Netw Learn Syst. 2018 Feb 5. doi: 10.1109/TNNLS.2018.2791644. [Epub ahead of print]

PMID:
29994428
15.

Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases.

Morabito F, Shanafelt TD, Gentile M, Reda G, Mauro FR, Rossi D, Di Renzo N, Molica S, Angrilli F, Chiarenza A, Cutrona G, Chaffee KG, Parikh SA, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Cortelezzi A, Gaidano G, Di Raimondo F, Fais F, Foà R, Neri A, Ferrarini M.

Am J Hematol. 2018 Sep;93(9):E216-E219. doi: 10.1002/ajh.25206. Epub 2018 Jul 30. No abstract available.

16.

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F.

Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20. No abstract available.

PMID:
29588545
17.

Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies.

Vigna E, Petrungaro A, Perri A, Terzi D, Recchia AG, Mendicino F, La Russa A, Bossio S, De Stefano L, Zinno F, Bonofiglio R, Morabito F, Gentile M.

Transfus Apher Sci. 2018 Apr;57(2):247-249. doi: 10.1016/j.transci.2018.03.005. Epub 2018 Mar 15.

PMID:
29567368
18.

Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence.

Cutrona G, Tripodo C, Matis S, Recchia AG, Massucco C, Fabbi M, Colombo M, Emionite L, Sangaletti S, Gulino A, Reverberi D, Massara R, Boccardo S, de Totero D, Salvi S, Cilli M, Pellicanò M, Manzoni M, Fabris S, Airoldi I, Valdora F, Ferrini S, Gentile M, Vigna E, Bossio S, De Stefano L, Palummo A, Iaquinta G, Cardillo M, Zupo S, Cerruti G, Ibatici A, Neri A, Fais F, Ferrarini M, Morabito F.

Sci Transl Med. 2018 Feb 14;10(428). pii: eaal1571. doi: 10.1126/scitranslmed.aal1571.

PMID:
29444977
19.

Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.

Gentile M, Shanafelt TD, Mauro FR, Laurenti L, Rossi D, Molica S, Vincelli I, Cutrona G, Uccello G, Pepe S, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F.

Am J Hematol. 2018 Feb;93(2):E35-E37. doi: 10.1002/ajh.24960. Epub 2017 Nov 23. No abstract available.

20.

Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation.

Patriarca F, Bruno B, Einsele H, Spina F, Giaccone L, Montefusco V, Isola M, Nozzoli C, Nozza A, Morabito F, Corradini P, Fanin R.

Biol Blood Marrow Transplant. 2018 Feb;24(2):406-409. doi: 10.1016/j.bbmt.2017.10.014. Epub 2017 Oct 12.

21.

Venetoclax for the treatment of chronic lymphocytic leukemia.

Gentile M, Petrungaro A, Uccello G, Vigna E, Recchia AG, Caruso N, Bossio S, De Stefano L, Palummo A, Storino F, Martino M, Morabito F.

Expert Opin Investig Drugs. 2017 Nov;26(11):1307-1316. doi: 10.1080/13543784.2017.1386173. Epub 2017 Oct 9. Review.

PMID:
28972395
22.

High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.

Vigneri P, Stagno F, Stella S, Cupri A, Forte S, Massimino M, Antolino A, Siragusa S, Mannina D, Impera SS, Musolino C, Malato A, Mineo G, Tomaselli C, Murgano P, Musso M, Morabito F, Molica S, Martino B, Manzella L, Müller MC, Hochhaus A, Raimondo FD.

Clin Cancer Res. 2017 Dec 1;23(23):7189-7198. doi: 10.1158/1078-0432.CCR-17-0962. Epub 2017 Sep 19.

23.

Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.

Petrungaro A, Gentile M, Mazzone C, Greco R, Uccello G, Recchia AG, De Stefano L, Bossio S, Palummo A, Morelli R, Musolino C, Morabito F, Vigna E.

Chemotherapy. 2017;62(6):353-356. doi: 10.1159/000477714. Epub 2017 Aug 16.

24.

Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib.

Vigna E, Martino B, Bacci F, Recchia AG, Mendicino F, Morelli R, Mauro FR, Musolino C, Greco R, Lucia E, Sabattini E, Morabito F, Gentile M.

Chemotherapy. 2017;62(6):350-352. doi: 10.1159/000477796. Epub 2017 Jul 26.

25.

Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model.

Martino M, Console G, Russo L, Meliado' A, Meliambro N, Moscato T, Irrera G, Messina G, Pontari A, Morabito F.

Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):506-512. doi: 10.1016/j.clml.2017.05.018. Epub 2017 Jun 6.

PMID:
28647402
26.

Permutation Disalignment Index as an Indirect, EEG-Based, Measure of Brain Connectivity in MCI and AD Patients.

Mammone N, Bonanno L, Salvo S, Marino S, Bramanti P, Bramanti A, Morabito FC.

Int J Neural Syst. 2017 Aug;27(5):1750020. doi: 10.1142/S0129065717500204. Epub 2017 Feb 9.

PMID:
28355927
27.

Basal CD34+ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony-Stimulating Factor: A Longitudinal, Prospective, Observational, Single-Center, Cohort Study.

Martino M, Gori M, Pitino A, Gentile M, Dattola A, Pontari A, Vigna E, Moscato T, Recchia AG, Barilla' S, Tripepi G, Morabito F.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1215-1220. doi: 10.1016/j.bbmt.2017.03.024. Epub 2017 Mar 24.

28.

Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.

Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foà R, Gentile M.

Am J Hematol. 2017 Jun;92(6):529-535. doi: 10.1002/ajh.24714. Epub 2017 Apr 18.

29.

Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.

Mauro FR, Morabito F, Vincelli ID, Petrucci L, Campanelli M, Salaroli A, Uccello G, Petrungaro A, Ronco F, Raponi S, Nanni M, Neri A, Ferrarini M, Guarini AR, Foà R, Gentile M.

Leuk Res. 2017 Jun;57:65-71. doi: 10.1016/j.leukres.2017.02.011. Epub 2017 Feb 27.

PMID:
28292720
30.

Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase.

Molica S, Giannarelli D, Mirabelli R, Levato L, Gentile M, Morabito F, Montserrat E.

Am J Hematol. 2017 Jun;92(6):E91-E93. doi: 10.1002/ajh.24707. Epub 2017 Mar 24. No abstract available.

31.

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.

Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3.

PMID:
28162984
32.

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.

Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, Rivas-Delgado A, Morabito F, Pospisilova S, Montserrat E.

Am J Hematol. 2017 Apr;92(4):375-380. doi: 10.1002/ajh.24660. Epub 2017 Feb 13.

33.

Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression.

Barisione G, Fabbi M, Cutrona G, De Cecco L, Zupo S, Leitinger B, Gentile M, Manzoni M, Neri A, Morabito F, Ferrarini M, Ferrini S.

Blood Cancer J. 2017 Jan 6;6(1):e513. doi: 10.1038/bcj.2016.121. No abstract available.

34.

Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.

Cutrona G, Matis S, Colombo M, Massucco C, Baio G, Valdora F, Emionite L, Fabris S, Recchia AG, Gentile M, Neumaier CE, Reverberi D, Massara R, Boccardo S, Basso L, Salvi S, Rosa F, Cilli M, Zupo S, Truini M, Tassone P, Calabrese M, Negrini M, Neri A, Morabito F, Fais F, Ferrarini M.

Leukemia. 2017 Sep;31(9):1894-1904. doi: 10.1038/leu.2016.394. Epub 2017 Jan 5.

PMID:
28053325
35.

Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.

Gentile M, Magarotto V, Offidani M, Musto P, Bringhen S, Teresa Petrucci M, Gay F, Larocca A, Uccello G, Petrungaro A, Vigna E, Greco R, Grazia Recchia A, Tripepi G, Ria R, Di Raimondo F, Palumbo A, Morabito F.

Am J Hematol. 2017 Mar;92(3):244-250. doi: 10.1002/ajh.24621. Epub 2017 Jan 23.

36.

Pomalidomide in multiple myeloma.

Uccello G, Petrungaro A, Mazzone C, Recchia AG, Greco R, Mendicino F, Lucia E, Vigna E, Morabito F, Gentile M.

Expert Opin Pharmacother. 2017 Feb;18(2):133-137. doi: 10.1080/14656566.2016.1274973. Epub 2016 Dec 26. No abstract available.

PMID:
28002973
37.

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA.

Clin Cancer Res. 2017 Jun 1;23(11):2891-2904. doi: 10.1158/1078-0432.CCR-16-1025. Epub 2016 Nov 30.

38.

Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI).

Molica S, Giannarelli D, Levato L, Mirabelli R, Gentile M, Morabito F.

Leuk Lymphoma. 2017 Jul;58(7):1736-1739. doi: 10.1080/10428194.2016.1257791. Epub 2016 Nov 22. No abstract available.

PMID:
27875912
39.

The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.

Molica S, Shanafelt TD, Giannarelli D, Gentile M, Mirabelli R, Cutrona G, Levato L, Di Renzo N, Di Raimondo F, Musolino C, Angrilli F, Famà A, Recchia AG, Chaffee KG, Neri A, Kay NE, Ferrarini M, Morabito F.

Am J Hematol. 2016 Nov;91(11):1090-1095. doi: 10.1002/ajh.24493. Epub 2016 Aug 8.

40.

lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome.

Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, Matis S, Colombo M, Galletti S, Taiana E, Recchia AG, Bossio S, Gentile M, Musolino C, Di Raimondo F, Grilli A, Bicciato S, Cortelezzi A, Tassone P, Morabito F, Ferrarini M, Neri A.

Blood Cancer J. 2016 Sep 9;6(9):e468. doi: 10.1038/bcj.2016.77.

41.

Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.

Gentile M, Shanafelt TD, Rossi D, Laurenti L, Mauro FR, Molica S, Cutrona G, Uccello G, Campanelli M, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F.

Blood. 2016 Oct 20;128(16):2093-2095. doi: 10.1182/blood-2016-07-728261. Epub 2016 Aug 22. No abstract available.

42.

Panobinostat for the treatment of acute myelogenous leukemia.

Morabito F, Voso MT, Hohaus S, Gentile M, Vigna E, Recchia AG, Iovino L, Benedetti E, Lo-Coco F, Galimberti S.

Expert Opin Investig Drugs. 2016 Sep;25(9):1117-31. doi: 10.1080/13543784.2016.1216971. Epub 2016 Aug 8. Review.

PMID:
27485472
43.

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

Pozzi S, Gentile M, Sacchi S, Marcheselli R, Corso A, Cocito F, Musto P, Guarini A, Minoia C, Vincelli I, Ria R, Rivolti E, Mele G, Bari A, Mazzone C, Badiali S, Marcheselli L, Palumbo A, Morabito F.

Leuk Lymphoma. 2017 Mar;58(3):552-559. doi: 10.1080/10428194.2016.1205741. Epub 2016 Jul 21.

PMID:
27442600
44.

Deep Learning Representation from Electroencephalography of Early-Stage Creutzfeldt-Jakob Disease and Features for Differentiation from Rapidly Progressive Dementia.

Morabito FC, Campolo M, Mammone N, Versaci M, Franceschetti S, Tagliavini F, Sofia V, Fatuzzo D, Gambardella A, Labate A, Mumoli L, Tripodi GG, Gasparini S, Cianci V, Sueri C, Ferlazzo E, Aguglia U.

Int J Neural Syst. 2017 Mar;27(2):1650039. doi: 10.1142/S0129065716500398. Epub 2016 May 3.

PMID:
27440465
45.

A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI).

Valdora F, Cutrona G, Matis S, Morabito F, Massucco C, Emionite L, Boccardo S, Basso L, Recchia AG, Salvi S, Rosa F, Gentile M, Ravina M, Pace D, Castronovo A, Cilli M, Truini M, Calabrese M, Neri A, Neumaier CE, Fais F, Baio G, Ferrarini M.

Clin Immunol. 2016 Nov;172:52-60. doi: 10.1016/j.clim.2016.07.013. Epub 2016 Jul 16.

46.

Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.

Gentile M, Zirlik K, Ciolli S, Mauro FR, Di Renzo N, Mastrullo L, Angrilli F, Molica S, Tripepi G, Giordano A, Di Raimondo F, Selleri C, Coscia M, Musso M, Orsucci L, Mannina D, Rago A, Giannotta A, Ferrara F, Herishanu Y, Shvidel L, Tadmor T, Scortechini I, Ilariucci F, Murru R, Guarini A, Musuraca G, Mineo G, Vincelli I, Arcari A, Tarantini G, Caparrotti G, Chiarenza A, Levato L, Villa MR, De Paolis MR, Zinzani PL, Polliack A, Morabito F.

Eur J Cancer. 2016 Jun;60:154-65. doi: 10.1016/j.ejca.2016.03.069. Epub 2016 Apr 27.

PMID:
27127905
47.

A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.

Martino M, Tripepi G, Messina G, Vincelli ID, Console G, Recchia AG, Gentile M, Molica S, Morabito F.

Bone Marrow Transplant. 2016 Sep;51(9):1197-203. doi: 10.1038/bmt.2016.94. Epub 2016 Apr 18.

PMID:
27088375
48.

Sorafenib for the treatment of multiple myeloma.

Gentile M, Martino M, Recchia AG, Vigna E, Morabito L, Morabito F.

Expert Opin Investig Drugs. 2016 Jun;25(6):743-9. doi: 10.1517/13543784.2016.1169272. Epub 2016 Apr 6. Review.

PMID:
26998658
49.

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.

Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Montefusco V, Passera R, De Rosa L, Omedé P, Vincelli ID, Spada S, Carella AM, Ponticelli E, Derudas D, Genuardi M, Guglielmelli T, Nozzoli C, Aghemo E, De Paoli L, Conticello C, Musolino C, Offidani M, Boccadoro M, Sonneveld P, Palumbo A.

Leukemia. 2016 Jun;30(6):1320-6. doi: 10.1038/leu.2016.36. Epub 2016 Feb 22.

50.

Long-term molecular remission in Philadelphia-positive acute lymphoblastic leukemia elderly patient after dasatinib discontinuation.

Vigna E, Gentile M, Giagnuolo G, Recchia AG, Bossio S, De Stefano L, Morelli R, Morabito F.

Leuk Lymphoma. 2016 Oct;57(10):2445-7. doi: 10.3109/10428194.2016.1140163. Epub 2016 Feb 15. No abstract available.

PMID:
26879289

Supplemental Content

Loading ...
Support Center